Pancreatic Cancer Research

ResearcherWakayama Medical UniversityActive in the last 2 years

Motoki Miyazawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9439-6792; OpenAlex author ID A5040216764. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: none · 2019: 2 papers · 2020: 4 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 25

  1. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00432-023-05594-1↗
  2. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2023.06.012↗
  3. Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Contro… Co-author DOI 10.1097/xcs.0000000000000408↗
  4. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by… Co-author DOI 10.1245/s10434-021-10985-0↗
  5. Advances in immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.944↗
  6. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreat… Co-author DOI 10.1016/j.ejso.2021.06.005↗
  7. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  8. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Co-author DOI 10.1007/s00423-020-01857-4↗
  9. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… Co-author DOI 10.1097/md.0000000000018718↗
  10. Preoperative In-Hospital Rehabilitation Improves Physical Function in Patients with Pancreatic Cancer Scheduled for Surgery. Co-author DOI 10.1620/tjem.251.279↗
  11. Preoperative Scoring System to Predict Prognosis in Patients Who Undergo Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14399↗
  12. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2018.12.015↗
  13. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… First author DOI 10.1186/s13063-019-3332-5↗
  14. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12013↗
  15. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Co-author DOI 10.1002/ijc.30510↗
  16. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11389↗
  17. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Co-author DOI 10.1007/s00280-016-3121-8↗
  18. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. Co-author DOI 10.1097/mpa.0000000000000634↗
  19. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  20. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.109↗
  21. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2323-6↗
  22. [Current topics and future to vaccine for pancreatic cancer]. Co-author DOI 10.3950/jibiinkoka.116.573↗
  23. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/j.1349-7006.2012.02214.x↗
  24. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. Co-author DOI 10.1016/j.canlet.2011.02.013↗
  25. [The development of a novel cancer vaccine using Peptide vaccine for patients with advanced pancreatic cancer]. Co-author PMID 22202233↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroki Yamaue · 24 shared papers, 2011–2024 · strength 2.14
  2. Manabu Kawai · 20 shared papers, 2012–2024 · strength 1.95
  3. Yuji Kitahata · 18 shared papers, 2012–2024 · strength 1.85
  4. Seiko Hirono · 19 shared papers, 2012–2023 · strength 1.78
  5. Ken‐ichi Okada · 18 shared papers, 2012–2024 · strength 1.76
  6. Atsushi Shimizu · 9 shared papers, 2012–2024 · strength 0.75
  7. Hideki Motobayashi · 3 shared papers, 2022–2024 · strength 0.49
  8. Atsushi Miyamoto · 3 shared papers, 2022–2024 · strength 0.49
  9. Tomohiro Yoshimura · 2 shared papers, 2023–2024 · strength 0.33
  10. Masahiro Katsuda · 4 shared papers, 2011–2021 · strength 0.31
  11. Masayuki Kitano · 3 shared papers, 2019–2021 · strength 0.28
  12. Ken Kouda · 2 shared papers, 2020–2022 · strength 0.26
  13. Ryohei Kobayashi · 2 shared papers, 2019–2021 · strength 0.22
  14. Yuki Kawaji · 2 shared papers, 2020–2021 · strength 0.21
  15. Keiichi Hatamaru · 2 shared papers, 2020–2021 · strength 0.21
  16. Masahiro Itonaga · 2 shared papers, 2020–2021 · strength 0.21
  17. Takashi Tamura · 2 shared papers, 2020–2021 · strength 0.21
  18. Yasunobu Yamashita · 2 shared papers, 2020–2021 · strength 0.21
  19. Ken‐ichi Okada · 2 shared papers, 2014–2021 · strength 0.19
  20. Sohei Satoi · 3 shared papers, 2014–2019 · strength 0.16
  21. Masaji Tani · 4 shared papers, 2012–2015 · strength 0.15
  22. Akio Katanuma · 2 shared papers, 2017–2019 · strength 0.13
  23. Tatsuya Ioka · 2 shared papers, 2016–2019 · strength 0.13
  24. Masayuki Furukawa · 2 shared papers, 2015–2019 · strength 0.11
  25. Tomoya Emori · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.